4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-20-064857
Executive VP, Head of R&D sold 23,551 shares at an average $149.23 ($3,514,610)
- Executive VP, Head of R&D acquired 23,551 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Option exercise | +23,551 | $16.90 | $398,012 | 57,515 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −1,700 | $148.11 | $251,787 | 55,815 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −900 | $149.18 | $134,262 | 54,915 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −1,600 | $150.16 | $240,256 | 53,315 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −1,100 | $151.58 | $166,738 | 52,215 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −500 | $152.41 | $76,205 | 51,715 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −1,400 | $147.05 | $205,870 | 50,315 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −8,400 | $148.38 | $1,246,392 | 41,915 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −5,000 | $149.73 | $748,650 | 36,915 | D |
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Sale | −2,951 | $150.61 | $444,450 | 33,964 | D |
| Derivatives | |||||||
| Ho Tony W Executive VP, Head of R&D | 2020-12-21 | Option exercise · Stock Option (right to buy) | −23,551 | 236,449 | D | ||
| Open-market sales · 23,551 sh · avg $149.23 · $3,514,610 | |||||||
Loading xslF345X03/doc4.xml…